Summary:
We sion. Measurement of C100-3 antibody by ELISA is known to sometimes yield falsepositive reactions. The high positive rate in dialysis patients may be partly due to some false-positive cases. Our results obtained by RIA, which is considered to produce less false-positive reactions, were similar to previously reported positive rates obtained by ELISA. Compared with the anti-HCV positive rate in the general population (1-2%), the antibody positive rate in dialysis patients is very high in Japan (Esteban et al. 1989; Oguchi et al. 1990) . In other countries, the anti-HCV positive rate in dialysis patients is also high (Evans et al. 1989) , and dialysis patients are considered to be a high risk group for HCV infection.
The anti-HCV positive rate in Japan was reported to be significantly higher than that in western countries, and its cause should be clarified. In this study, HCV infection due to blood transfusion alone could not explain the high antibody positive rate in dialysis patients.
In long-term dialysis therapy, the possibility of HCV infection by routes other than blood transfusion should be also considered.
As infection routes other than blood transfusion, various environmental factors have been suggested such as an acupuncture or tattooing. The background factors of the patient should be also evaluated in detail. Recent studies suggested the possibility of HCV infection also in patients with hemophilia treated with only heated blood preparations when the use was frequent (Simmonds et al. 1990 ). In dialysis patients, in whom albumin preparations are used, the possibility that these blood preparations cause HCV infection cannot be excluded. This route should be evaluated in detail. The anti-HCV positive rate was 65.6% (21/32) in the dialysis patients with chronic liver disease and 22.0% (46/203) in those without chronic liver disease. A significant correlation was observed between chronic liver disease and anti-HCV (p<0.01). These results suggest that HCV infection is the cause of chronic liver disease in dialysis patients.
This may also support the hypothesis that the C100-3 antibody, i. e., the antibody against the NS 3, 4 region of the HCV gene, is involved in the development of chronic liver disease. Recently, antibody against the core region of HCV can be also measured. The state of HCV infection should be studied in more detail using this measurement system.
